Risk factor
Very poor trading liquidity
Profitability factor
Strong growth
About
PT Murni Sadar Tbk, together with its subsidiaries, provides health services and manages private hospitals in Indonesia. The company offers outpatient installation services, including specialist, family health, general, dental, tropical diseases, travel medicine, and pain clinics; laboratory services, such as clinical pathology, blood bank, biomolecular/PCR, microbiology, and anatomical pathology; radiotherapy, consists of LINAC, CT-simulator and immobilization, treatment planning system, and brachytherapy services. It also provides radiology services, including general X-Ray, ultrasonography (USG), mammography, 128 slice CT scan, 1.5 Tesla MRI, and interventional radiology; heart & vascular center, such as ECG, treadmill test, echocardiology, holter monitoring, and cardiac catheterization laboratory; endoscopy, contain esophagoscopy, gastroscopy, colonoscopy, bronchoscopy, and ERCP; medical rehabilitation, comprising physiotherapy, speech and occupation therapy, and orthotic prosthetic. In addition, the company offers general services, which includes emergency installation, and inpatient facility; intensive care; public facilities; operating theatres, ESWL, laporoscopic surgery, oncology, chemotherapy, pharmaceutical installations, medical checkup, lifestyle clinic, murni teguh IVF, home care, palliative care, EEG, EMG, and ambulance services; as well as operates IVF Centre. Further, it provides general facilities such as, auditorium, cafeteria, commercials area, fitness gym, and homestay. PT Murni Sadar Tbk was founded in 2010 and is based in Medan, Indonesia.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value on EV/